FAP Protein, Human (HEK293, hFc)
Based on 1 Customer Validation
The FAP protein is a cell surface glycoprotein serine protease that is critical for extracellular matrix degradation and plays multiple roles in tissue remodeling, fibrosis, wound healing, inflammation, and tumor growth. FAP Protein, Human (HEK293, hFc) is the recombinant human-derived FAP protein, expressed by HEK293, with N-hFc labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
The FAP protein is a cell surface glycoprotein serine protease that is critical for extracellular matrix degradation and plays multiple roles in tissue remodeling, fibrosis, wound healing, inflammation, and tumor growth. FAP Protein, Human (HEK293, hFc) is the recombinant human-derived FAP protein, expressed by HEK293, with N-hFc labeled tag.
Background
FAP protein, a cell surface glycoprotein serine protease, plays a crucial role in extracellular matrix degradation and is involved in diverse cellular processes, including tissue remodeling, fibrosis, wound healing, inflammation, and tumor growth. Both the plasma membrane and soluble forms of FAP exhibit post-proline cleaving endopeptidase activity, demonstrating a preference for Ala/Ser-Gly-Pro-Ser/Asn/Ala consensus sequences on substrates such as alpha-2-antiplasmin SERPINF2 and SPRY2. FAP can degrade gelatin, heat-denatured type I collagen, and various other substrates. Additionally, it possesses dipeptidyl peptidase activity, hydrolyzing prolyl bonds in synthetic dipeptide substrates with a preference for specific amino acid sequences. In association with DPP4, PLAUR, or integrins, the plasma membrane form of FAP participates in pericellular proteolysis of the extracellular matrix, promoting cell adhesion, migration, and invasion. FAP's multifaceted functions extend to tissue remodeling during development and wound healing. In malignant melanoma cancers, FAP enhances cell invasiveness towards the extracellular matrix and promotes glioma cell invasion through the brain parenchyma by degrading the proteoglycan brevican. While contributing to tumor growth progression by increasing angiogenesis, collagen fiber degradation, and apoptosis, FAP paradoxically acts as a tumor suppressor in melanocytic cells through the regulation of cell proliferation and survival in a serine protease activity-independent manner.
Verified Bioactivity
1. Measured by its binding ability in a functional ELISA. Immobilized Human FAP, Fc Tag at 1 μg/mL (100 μL/well) can bind Anti-FAP Antibody, Mouse IgG2a (FAP5) with a linear range of 0.2-3 ng/mL.
2. Measured by its ability to convert the substrate benzyloxycarbonyl-Gly-Pro-7-amido-4- methylcoumarin (Z-GP-AMC) to Z-Gly-Pro and 7-amino-4-methylcoumarin (AMC). The specific activity is >7000 pmol/min/µg.
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag N-hFc
-
Accession
Q12884-1 (L26-D760)
-
Gene ID2191
-
Molecular Construction
-
N-term
-
hFc
-
FAP (L26-D760)
Accession # Q12884 -
C-term
-
-
Protein Length
Full Length of Antiplasmin-cleaving enzyme FAP, soluble form
-
Synonyms
FAP; Prolyl Endopeptidase FAP; Fibroblast Activation Protein Alpha; Dipeptidyl Peptidase FAP; Seprase; FAPalpha; DPPIV; SIMP; 170 KDa Melanoma Membrane-Bound Gelatinase; CDNA FLJ60298, Highly Similar To Seprase; Gelatine Degradation Protease FAP; Fibrobla
-
AA Sequence
LRPSRVHNSEENTMRALTLKDILNGTFSYKTFFPNWISGQEYLHQSADNNIVLYNIETGQSYTILSNRTMKSVNASNYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCWSPVGSKLAYVYQNNIYLKQRPGDPPFQITFNGRENKIFNGIPDWVYEEEMLATKYALWWSPNGKFLAYAEFNDTDIPVIAYSYYGDEQYPRTINIPYPKAGAKNPVVRIFIIDTTYPAYVGPQEVPVPAMIASSDYYFSWLTWVTDERVCLQWLKRVQNVSVLSICDFREDWQTWDCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKDTVENAIQITSGKWEAINIFRVTQDSLFYSSNEFEEYPGRRNIYRISIGSYPPSKKCVTCHLRKERCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQEIKILEENKELENALKNIQLPKEEIKKLEVDEITLWYKMILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVNWISYLASKEGMVIALVDGRGTAFQGDKLLYAVYRKLGVYEVEDQITAVRKFIEMGFIDEKRIAIWGWSYGGYVSSLALASGTGLFKCGIAVAPVSSWEYYASVYTERFMGLPTKDDNLEHYKNSTVMARAEYFRNVDYLLIHGTADDNVHFQNSAQIAKALVNAQVDFQAMWYSDQNHGLSGLSTNHLYTHMTHFLKQCFSLSD
-
Predicted Molecular Mass
111.5 kDa
-
Molecular Weight
Approximately 120-130 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Structure/Form
Homodimer
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder
Lyophilized from 0.22 μm filtered solution of PBS, pH7.4 with 10% trehalose as protectant.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (241 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)